Longeveron appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer effective April 4, 2022

Longeveron Inc.

Dr. Min will lead global clinical development and regulatory strategy; focus on advancing Lomecel-B into pivotal trials and approval.
Compensation: base salary $350k, performance bonus 30%, $60k signing bonus (half RSUs, half options), plus 150k RSUs and 50k stock options vesting over 4 years.
Dr. Min brings over a decade of pharma/biotech experience including roles at Merck, Cerevel, BlueRock, and Enterin; board-certified neurologist.
Annual shareholder meeting set for June 24, 2022; proposal deadlines: Rule 14a-8 proposals due May 6, other business notice due June 17.

item 5.02 item 5.08 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

K. Chris Min, M.D., Ph.D.

Chief Medical Officer

LGVN · Longeveron Inc.

Effective: 2022-04-04
Filed: April 5, 2022, 7:59 PM ET

On April 5, 2022, Longeveron Inc. (“Longeveron”) announced the appointment of K. Chris Min, M.D., Ph.D. to the Longeveron executive leadership team in the role of Chief Medical Officer (CMO), effective April 4, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

K. Chris Min, M.D., Ph.D. was appointed as Chief Medical Officer at Longeveron Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On April 5, 2022, Longeveron Inc. (“Longeveron”) announced the appointment of K. Chris Min, M.D., Ph.D. to the Longeveron executive leadership team in the role of Chief Medical Officer (CMO), effective April 4, 2022.

View on SEC.gov

Longeveron Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-018143

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.